Today's biopharmaceutical landscape is witnessing an increase in complex next-generation biological molecules. These molecules, characterized by their intricate structures and deviations from traditional antibody formats, pose unique challenges for manufacturers.
In this recent webinar, Ian Anderson, Global Senior Principal Scientist at Lonza, delves into sophisticated analytical strategies designed to streamline process characterization to support BLA submission for next-generation biological molecules.
Watch on-demand for key insights:
- Comprehensive BLA process characterization strategies: Learn about the latest methods Lonza employs to simplify and enhance process characterization for new molecular entities, ensuring robust and reliable outcomes.
- Technological innovations: Explore cutting-edge technologies such as multi-attribute methods (MAM) and dual-band analysis that significantly reduce time, cost, and complexity in your BLA pipeline.
- Real-world case studies: Gain valuable knowledge from real-world case studies that demonstrate how Lonza's pioneering approaches have successfully supported BLA submissions and commercial success.
